Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gentamicin + metronidazole is a combination of two antibiotics used primarily for the prevention and treatment of mixed aerobic and anaerobic bacterial infections, especially in surgical settings such as abdominal or gynecological procedures. Gentamicin is an aminoglycoside antibiotic that acts by binding to the 30S ribosomal subunit, inhibiting protein synthesis in susceptible Gram-negative bacteria. Metronidazole is a nitroimidazole antibiotic effective against most anaerobic bacteria and certain protozoa; it works by disrupting DNA synthesis after reduction within anaerobic cells. The combination provides broad-spectrum coverage against both aerobic (gentamicin) and anaerobic (metronidazole) pathogens, making it particularly useful for prophylaxis in surgeries with high risk of contamination or infection involving both types of organisms[1][2][5]. Clinical studies have shown that this combination can be more effective than either agent alone for preventing post-surgical infections, including intra-abdominal abscesses and post-caesarean wound infections[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamicin + metronidazole.